Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow CRSP by emailGet an email when CRSP pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about CRSP, unsubscribe in one click. Privacy
📣 What CRSP Says Is Next
second half of 2026 · “In immuno-oncology, the Phase 1/2 clinical trial of zugo-cel in B-cell malignancies is ongoing, with updates anticipated in the second half of 2026.”
Company press release, Aug 3, 2026 · SEC filing
second half of 2026 · “The Company recently received FDA clearance of its Investigational New Drug (IND) application, supporting expansion of the ongoing trial into the U.S. The Company expects to provide an update in the second half of 2026.”
Company press release, May 4, 2026 · SEC filing
in 2026 · “CTX321 is currently in IND/CTA-enabling studies, with an Lp(a) program update expected in 2026.”
Company press release, Feb 12, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Get the full CRSP picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CRSP and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.